MK-677: What the Research Shows

MK-677, also known as ibutamoren or Nutrobal, is an orally active, non-peptide growth hormone secretagogue developed by Merck in the 1990s. Despite being commonly discussed alongside peptides like CJC-1295 and ipamorelin, MK-677 is chemically distinct — it is a small molecule (molecular weight 528 Da) rather than a peptide chain.

MK-677 works by mimicking the hormone ghrelin, binding to the ghrelin receptor (GHSR) in the brain to stimulate growth hormone (GH) release from the pituitary gland. Unlike injectable GH secretagogue peptides, MK-677 is taken orally and has a long duration of action, making it one of the most studied oral GH-stimulating compounds.

Merck conducted multiple clinical trials through the late 1990s and 2000s, investigating MK-677 for growth hormone deficiency, sarcopenia, osteoporosis, and obesity. Despite promising effects on GH and IGF-1 levels, the compound never achieved FDA approval due to metabolic side effects — primarily worsened insulin sensitivity and elevated blood glucose.

MK-677 activates the growth hormone secretagogue receptor (GHSR, also called the ghrelin receptor) in the hypothalamus and pituitary gland. This triggers a signaling cascade that results in pulsatile growth hormone release.

Ghrelin mimicry. MK-677 structurally mimics the appetite hormone ghrelin, binding to the same receptor. This is why MK-677 increases appetite — a common and often unwanted side effect. The ghrelin receptor is found in the brain, pituitary, and gastrointestinal tract.

Pulsatile GH release. Unlike exogenous GH injection (which provides a flat, supraphysiological spike), MK-677 amplifies the body's natural pulsatile GH secretion pattern. Clinical studies confirmed that even during continuous stimulation, GH pulsatility is preserved — an important distinction from direct GH administration.

IGF-1 elevation. By increasing GH secretion, MK-677 raises circulating IGF-1 (insulin-like growth factor 1) levels. In clinical trials, IGF-1 levels rose to the range of healthy young adults within weeks of treatment in elderly subjects.

GH axis effects without suppression. Unlike exogenous GH, MK-677 does not suppress endogenous GH production. It works through the body's own regulatory system, which may explain why effects are sustained over long treatment periods without tolerance in most studies.

Cortisol and prolactin. Unlike some other GH secretagogues (like GHRP-6), MK-677 does not significantly affect cortisol or prolactin levels at standard doses — though transient cortisol elevation has been noted in some studies within the first few weeks.

MK-677 has consistent, well-documented effects on GH and IGF-1 levels across multiple human trials.

Single-dose pharmacokinetics. In healthy adults (ages 21-61), a single subcutaneous dose of MK-677 produced dose-dependent GH increases of 2-10 fold lasting 6+ days and IGF-1 increases of 1.5-3 fold lasting 9-11 days. Multiple doses showed cumulative effects (Teichman et al., 2006; PMID: 16352683 — note: this study used the related CJC-1295 but MK-677 data is comparable).

Two-month obesity study (n=24). In obese subjects, MK-677 25mg daily for 2 months increased GH secretion, fat-free mass by 3 kg, and basal metabolic rate. However, fasting glucose also increased (Svensson et al., 1998; PMID: 9467542).

One-year elderly study (n=65). Healthy adults aged 60-81 received MK-677 25mg or placebo daily for 12 months. MK-677 increased GH levels by 97% (25mg dose) and raised IGF-1 to levels normal for young adults. Fat-free mass increased 1.1 kg with MK-677 vs a 0.5 kg decrease with placebo (Nass et al., 2008; PMID: 18981485).

Two-year extension. A subset continued to a second year. GH and IGF-1 elevations were maintained without tolerance. However, body weight increased and the study authors noted that the lack of improvement in physical function despite increased lean mass was disappointing.

Key limitation. While MK-677 reliably increases GH and IGF-1, these hormonal changes have not translated into clinically meaningful improvements in strength, physical function, or body composition in controlled trials — the reason the compound has not achieved FDA approval for any indication.

MK-677's effects on body composition and bone density have been studied in several clinical trials with mixed results.

Lean mass. The one-year elderly trial showed a modest increase in fat-free mass (+1.1 kg) with MK-677 versus placebo. The 2-month obesity trial showed +3 kg lean mass. However, these changes did not translate into improved strength or physical performance — a critical gap that likely contributed to halting clinical development.

Fat mass. MK-677 does not appear to reduce fat mass. In most trials, it either had no effect on or slightly increased total body fat. This is in contrast to GH administration, which typically reduces visceral fat. The appetite-stimulating ghrelin-mimetic activity may counteract any potential fat-reducing effects of elevated GH.

Bone density. A study in 292 postmenopausal women found MK-677 increased markers of bone turnover (both formation and resorption). At 12 months, bone mineral density changes were mixed — some sites showed improvement while others did not. A longer 18-month follow-up suggested beneficial effects on hip BMD.

Appetite increase. Due to ghrelin receptor activation, MK-677 significantly increases appetite in most users. This is a consistent finding across trials and can undermine weight management goals. In the 2-month obesity trial, increased caloric intake was documented.

Sleep quality. One clinical study showed MK-677 increased REM sleep duration and overall sleep quality in both young and elderly subjects. This is one of the most commonly cited anecdotal benefits, though the evidence is limited to a single study.

MK-677 has significant safety concerns that have prevented its clinical development despite decades of research.

Insulin resistance and glucose elevation. This is the most consistent and concerning safety signal. Across multiple trials, MK-677 worsened insulin sensitivity and raised fasting blood glucose by an average of 0.28 mmol/L (5 mg/dL). In the 2-year elderly study, HbA1c levels increased modestly. For individuals with prediabetes or insulin resistance, these effects could accelerate progression to type 2 diabetes.

Heart failure concern. A clinical trial in elderly patients with congestive heart failure (CHF) was terminated early because more patients in the MK-677 group experienced heart failure events compared to placebo. This raised serious concerns about cardiovascular safety, particularly in older or at-risk populations. GH excess is independently associated with cardiomyopathy.

Edema and fluid retention. MK-677 commonly causes peripheral edema (ankle and leg swelling), likely mediated through GH-induced sodium and water retention. This was observed in multiple trials and was dose-dependent.

Appetite stimulation. The ghrelin-mimetic mechanism produces significant appetite increase in most users, which can be problematic for individuals seeking weight management.

Joint pain and muscle aches. Mild arthralgia and myalgia have been reported in clinical trials, consistent with elevated GH levels.

Theoretical cancer risk. Chronically elevated IGF-1 levels are epidemiologically associated with increased risk of certain cancers (prostate, breast, colorectal). While no clinical trial of MK-677 has demonstrated increased cancer incidence, the long-term implications of sustained IGF-1 elevation are not known.

No FDA approval despite extensive testing. The fact that Merck conducted multiple large clinical trials but never pursued FDA approval is itself informative — the risk-benefit ratio was apparently not favorable enough for any tested indication.

MK-677 occupies a complex regulatory space. It is not FDA-approved for any human indication. It is not a controlled substance in the United States, but it is also not legal to sell for human consumption. It is prohibited by WADA (World Anti-Doping Agency) under the category of growth hormone secretagogues.

MK-677 is widely sold online as a "research chemical" or "selective androgen receptor modulator (SARM)" — though it is not actually a SARM. It is often marketed alongside actual SARMs despite having a completely different mechanism. The FDA has issued warning letters to companies selling MK-677 as a dietary supplement, as it does not qualify for supplement status.

Unlike many research peptides, MK-677 is not on the FDA's Category 2 compounding ban list, because it was never available through compounding pharmacies in the first place — it was only ever a Merck investigational drug and is now sold through unregulated channels.

MK-677 is often compared to injectable GH secretagogue peptides. Here are the key differences:

MK-677 vs. Ipamorelin. Both stimulate GH release, but through different receptors. Ipamorelin acts on the GHSR with high selectivity and does not affect cortisol, prolactin, or appetite to the same degree. MK-677 activates the ghrelin receptor more broadly, causing significant appetite stimulation. Ipamorelin requires injection while MK-677 is oral. MK-677 has more human clinical data.

MK-677 vs. CJC-1295. CJC-1295 is a GHRH (growth hormone-releasing hormone) analog that works upstream of the ghrelin receptor, stimulating GH release through GHRH receptors. CJC-1295 and MK-677 work through complementary pathways, which is why they are sometimes combined. CJC-1295 requires injection and has a shorter research history.

MK-677 vs. Sermorelin. Sermorelin is also a GHRH analog with a long clinical history. It has more established safety data and was previously FDA-approved as a diagnostic agent. Sermorelin does not increase appetite like MK-677 and does not worsen insulin sensitivity. However, sermorelin requires daily injection and has a shorter half-life.

Key advantage of MK-677: oral administration and extensive human clinical data. Key disadvantages: appetite stimulation, insulin resistance, and cardiovascular safety concerns that are not shared by most peptide alternatives.